BioDelivery Sciences International (NASDAQ:BDSI) Upgraded at BidaskClub

BidaskClub upgraded shares of BioDelivery Sciences International (NASDAQ:BDSI) from a sell rating to a hold rating in a research report released on Monday morning, BidAskClub reports.

BDSI has been the topic of a number of other research reports. Cantor Fitzgerald set a $8.00 price objective on BioDelivery Sciences International and gave the stock a buy rating in a research note on Friday, May 10th. Zacks Investment Research upgraded BioDelivery Sciences International from a hold rating to a buy rating and set a $5.00 price objective on the stock in a research note on Tuesday, May 21st. Finally, ValuEngine lowered BioDelivery Sciences International from a hold rating to a sell rating in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company’s stock. BioDelivery Sciences International currently has an average rating of Buy and an average target price of $6.20.

BioDelivery Sciences International stock opened at $4.30 on Monday. The stock’s fifty day moving average price is $4.11 and its two-hundred day moving average price is $4.56. BioDelivery Sciences International has a one year low of $2.55 and a one year high of $5.37. The company has a debt-to-equity ratio of 1.90, a current ratio of 2.88 and a quick ratio of 2.57. The firm has a market cap of $383.16 million, a PE ratio of -5.89 and a beta of 0.48.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.12. BioDelivery Sciences International had a negative return on equity of 1.10% and a negative net margin of 34.73%. The firm had revenue of $29.68 million for the quarter, compared to analyst estimates of $25.30 million. Sell-side analysts expect that BioDelivery Sciences International will post -0.13 earnings per share for the current fiscal year.

In other news, Director Francis E. Odonnell, Jr. sold 8,000 shares of BioDelivery Sciences International stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $4.32, for a total value of $34,560.00. Following the transaction, the director now owns 612,754 shares in the company, valued at approximately $2,647,097.28. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Mark A. Sirgo sold 90,706 shares of BioDelivery Sciences International stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $4.39, for a total value of $398,199.34. Following the completion of the transaction, the director now owns 2,031,714 shares in the company, valued at approximately $8,919,224.46. The disclosure for this sale can be found here. In the last quarter, insiders sold 599,458 shares of company stock worth $2,546,413. Corporate insiders own 8.94% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of BDSI. BlackRock Inc. boosted its holdings in shares of BioDelivery Sciences International by 15.8% during the 4th quarter. BlackRock Inc. now owns 1,388,297 shares of the specialty pharmaceutical company’s stock valued at $5,137,000 after acquiring an additional 189,508 shares in the last quarter. Raymond James & Associates boosted its holdings in shares of BioDelivery Sciences International by 14.9% during the 4th quarter. Raymond James & Associates now owns 46,211 shares of the specialty pharmaceutical company’s stock valued at $171,000 after acquiring an additional 6,000 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of BioDelivery Sciences International by 56.3% during the 4th quarter. Advisor Group Inc. now owns 10,943 shares of the specialty pharmaceutical company’s stock valued at $40,000 after acquiring an additional 3,943 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of BioDelivery Sciences International by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 517,620 shares of the specialty pharmaceutical company’s stock valued at $1,915,000 after acquiring an additional 5,628 shares in the last quarter. Finally, Squarepoint Ops LLC acquired a new stake in shares of BioDelivery Sciences International during the 4th quarter valued at $147,000. Institutional investors own 57.51% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: What are some reasons analysts would give stocks a buy rating?

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.